More than 30 years after the company was established, ImmunoGen, Inc. is transitioning from an antibody-drug conjugate (ADC) developer into a commercial-stage company with the US Food and Drug Administration approval and upcoming launch of the company's first independently owned drug, Elahere (mirvetuximab soravtansine).
ImmunoGen Transitions To Commercial Stage With Elahere Launch
The antibody-drug conjugate was approved by the US FDA for the treatment of FRα-positive, platinum-resistant epithelial ovarian cancer.

More from Anticancer
More from Therapy Areas
• By
After a long wait for patients, Vykat has become the first drug approved for Prader-Willi syndrome symptoms, opening the market up for Soleno and future challengers.
• By
With its exon 53-skipping candidate already showing promise in 24-week data, Wave now has 48-week data showing improvements in muscle health and functional outcomes.
• By
J&J is confident that its bispecific antibody/kinase inhibitor combo’s overall survival win over AstraZeneca’s single-agent pill will shift the standard of care.